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ABSTRACT
Necroptosis is a regulated necrotic cell death that involves receptor-interacting 
protein kinases RIPK1 and RIPK3. Here, we report that edelfosine triggers a rapid and 
massive cell death in human glioblastoma cells with characteristics of necrosis. Only a 
minor proportion of edelfosine-treated cells underwent caspase-dependent apoptosis. 
Autophagy and a rapid influx of extracellular calcium into the cells had little impact 
on cell death. Levels of procaspase-8 were very low in necroptosis-prone glioma 
cells compared with the levels in other cancer cell types that underwent apoptosis 
upon edelfosine treatment. The RIPK1-dependent necroptosis inhibitors necrostatin-1 
(Nec-1) and Nec-1s as well as siRNA-mediated silencing of RIPK3 inhibited edelfosine-
induced necroptosis, resulting in increased caspase-dependent apoptosis in 
edelfosine-treated glioblastoma U118 cells. Inhibition of the RIPK3 substrate MLKL 
with necrosulfonamide also increased apoptosis in edelfosine-treated cells. These 
data support a major role for RIPK1 and RIPK3 in the induction of necrotic cell death 
and in the switch from necrosis to apoptosis following edelfosine treatment. These 
results indicate that the ether lipid edelfosine exerts a rapid necroptotic cell death in 
apoptosis-reluctant glioblastoma cells, suggesting that induction of necroptosis could 
constitute a new approach for glioblastoma therapy.
INTRODUCTION
Malignant glioma or glioblastoma is the most 
common and the most aggressive malignant primary brain 
tumor with a very poor prognosis. The survival rate for 
this tumor is extremely low because of its aggressiveness, 
ranging from about 3-4 months without treatment to up 
to a median survival of about 12-15 months following 
current medical therapy [1, 2]. Treatment of glioblastoma 
is a combined approach, including surgery, radiotherapy 
and chemotherapy. Current recommendations are based 
on radiotherapy combined with the oral alkylating drug 
temozolomide, which is able to cross the blood-brain 
barrier and exhibits a favorable side effect profile [3-5]. 
However, glioblastomas almost invariably recur near 
their initial sites leading rapidly to death [5, 6]. The 
cell death pathways induced by the triazene compound 
temozolomide in malignant glioma cells remain to be fully 
elucidated, but several studies have shown the induction of 
G2/M arrest and autophagy [7-9]. 
A number of survival signaling pathways can be 
activated constitutively in glioma cells, thus rendering 
these cells resistant to conventional chemotherapies and 
proapoptotic insults [10, 11]. The unfavorable prognosis 
for glioblastoma patients is strongly correlated to the 
intrinsic apoptosis resistance of glioblastoma cells [12, 
13]. On these grounds, induction of alternative types of cell 
death could be an option for the treatment of glioblastoma. 
Thus, autophagic cell death by pro-autophagic drugs has 
been recently considered as an alternative and emerging 
concept to trigger glioma cell death and to exploit caspase-
independent programmed cell death pathways for the 
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development of novel glioma therapies [12].
The ether phospholipid edelfosine (1-O-octadecyl-
2-O-methyl-rac-glycero-3-phosphocholine, ET-18-OCH3) 
is the prototype molecule of a family of unnatural lipids, 
collectively known as synthetic alkylphospholipid analogs 
(APLs), which promotes apoptosis in a variety of tumor 
cells [14-21]. Edelfosine has been shown to be an effective 
in vitro and in vivo antitumor drug, which acts through 
the reorganization of membrane domains, termed lipid 
rafts, as well as through an endoplasmic reticulum stress 
response, leading to caspase- and mitochondria-mediated 
apoptosis in different hematological and solid tumor cells 
[22-28].
Here we report that edelfosine induces mainly 
necroptosis in the U118 (U-118 MG) glioblastoma cell 
line, used as a brain tumor cell line model, whereas 
apoptosis and autophagy are relatively minor responses. 
Edelfosine-induced necroptototic response is very rapid 
and potent, thus suggesting a putative therapeutic role for 
necroptosis in brain tumor therapy. 
RESULTS
Edelfosine promotes rapid cell death in U118 
human glioma cells
Following MTT assays we found that incubation 
of the U118 human glioblastoma cell line with 10 µM 
edelfosine induced a rapid cell death response. U118 cells 
rapidly lost their ability to metabolize MTT following 
incubation with 10 µM edelfosine (Fig. 1A). Time-
lapse videomicroscopy showed dramatic morphological 
changes as early as 150-180 min upon drug addition, 
showing apparently necrotic cell death, including cell 
swelling, membrane bubbling and plasma membrane 
disruption (Fig. 1B; Supplementary Videos S1 and S2). 
Most of the cells (~80%) showed morphologic features 
of necrosis after 24-h treatment (data not shown). Loss 
of nuclear membrane integrity was also readily detected 
by DAPI staining (Fig. 1C). In contrast, staurosporine-
induced U118 cell death was accompanied by chromatin 
condensation, a typical hallmark of apoptosis, which was 
hardly observed following edelfosine treatment (Fig. 1D).
Induction of apoptosis in edelfosine-treated U118 
cells
Because edelfosine has been reported to promote a 
potent and typical apoptosis in a wide number of tumor 
cells [15-17, 23, 29], we analyzed this cell death response 
in edelfosine-treated U118 cells. Only ~18% of the U118 
cells treated with 10 µM edelfosine for 24 h displayed 
DNA degradation, as assessed by the percentage of cells 
in the sub-G1 region of cell cycle (Fig. 2A). This rather 
weak apoptotic response contrasted with the high DNA 
degradation detected following staurosporine treatment 
(Fig. 2A), used as a positive inducer for apoptosis [30]. 
Edelfosine treatment led to internucleosomal DNA 
degradation (Fig. 2B), a hallmark of apoptosis. In addition, 
edelfosine induced caspase-3 activation, as assessed 
by the appearance of the cleaved caspase-3 form, and 
the cleavage of poly(ADP-ribose) polymerase (PARP), 
a major caspase-3 substrate (Fig. 2C). Furthermore, 
Figure 1: Edelfosine promotes rapid cell death in U118 
human glioma cells. (A) U118 cells were incubated in the 
absence (Control) or presence of 10 μM edelfosine (EDLF) 
for the indicated time points and then analyzed by MTT assay. 
Data are expressed as means ± SD of at least three independent 
experiments, each one performed in triplicate. The right plot 
shows only the measurements for edelfosine (EDLF)-treated 
cells for an easier appreciation of changes. (B) Selected phase-
contrast time-lapse videomicroscopy frames (magnification, 
10x) from U118 cells untreated (Control) or treated with 10 μM 
edelfosine (EDLF) at the indicated times. Lower panels show 
cells undergoing explosive death. The elapsed times in minutes 
are indicated on top of each frame. (C) Cell morphology of U118 
cells untreated (Control) and treated with 10 μM edelfosine 
(EDLF) for 24 h. Differential interference contrast microscopy 
(DIC) and DAPI staining shows loss of plasma and nuclear 
membrane integrity after 24 h treatment. Magnification, 63x. 
Bar, 10 μm. (D) Brightfield microscopy (BF) and fluorescence 
microscopy photographs of DAPI-stained untreated control 
cells, cells treated with 10 μM edelfosine (EDLF) or with 0.5 
μM staurosporine (STS) for 4 h. Chromatin condensation can 
be seen in staurosporine-treated cells, but not in edelfosine 
treated cells. Brightfield image magnification, 20x. DAPI image 
magnification, 40x. Bar, 40 μm (BF); Bar, 20 μm (DAPI).
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preincubation with the pan-caspase inhibitor z-VAD-
fmk completely blocked edelfosine-induced apoptosis 
(Fig. 2D), but was unable to inhibit the overall cell death 
response exerted by edelfosine in U118 cells (Fig. 2E). 
These results indicate that the minor edelfosine-induced 
caspase-dependent apoptosis response cannot account for 
the massive cell death detected in edelfosine-treated U118 
cells.
Induction of autophagy in edelfosine-treated U118 
cells
The acidotropic agent acridine orange has been 
employed to monitor the development of acidic vesicular 
organelles (AVOs) during autophagy [31, 32]. We 
found an intense vital red fluorescence staining of U118 
Figure 2: Edelfosine induces a minor apoptotic response in U118 cells. (A) Representative cell cycle analysis histograms of 
untreated U118 cells (Control), U118 cells treated with 10 μM edelfosine (EDLF) for 24 h, and U118 cells treated with 0.5 μM staurosporine 
(STS) for 4 h. The percentage of apoptotic cells, identified as the sub-G1 population by flow cytometry, is indicated in each figure. (B) Cells 
treated with 10 μM edelfosine (EDLF) for 24 and 48 h were assayed for DNA fragmentation in agarose gels. Control untreated cells (C) 
were run in parallel in the same gels. A 123-bp DNA ladder was used as standard (Std). (C) Cells were untreated (Control, C) or treated with 
10 μM edelfosine (EDLF) for the indicated times, and then analyzed by immunoblotting using specific antibodies against cleaved caspase-3 
and PARP. Immunoblotting for β-actin was used as an internal control for equal protein loading in each lane. (D) Cells were preincubated 
without or with 100 μM pan-caspase inhibitor z-VAD-fmk (z-VAD) for 1 h, and then incubated in the absence (Control) or presence of 10 
μM edelfosine (EDLF) for 24 h. Cells were analyzed by flow cytometry to evaluate apoptosis as the percentage of sub-G1 population in 
cell cycle analysis. Data shown are means ± SD of three independent experiments. ***, P<0.001 EDLF vs. z-VAD+EDLF, Student’s t test. 
(E) MTT assays were conducted after culturing U118 cells without or with 100 μM pan-caspase inhibitor z-VAD-fmk (z-VAD) for 1 h, and 
then incubated in the absence (Control) or presence of 10 μM edelfosine (EDLF) at the indicated time points. Data are expressed as means 
± SD of three independent experiments, each one performed in triplicate. The lower plot shows only the measurements for edelfosine- and 
z-VAD-fmk+edelfosine-treated cells for an easier appreciation of changes.
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cells after edelfosine treatment (Fig. 3A), showing that 
edelfosine promotes the generation of acidic vacuoles 
in U118 cells. A major hallmark of autophagy lies in 
the conversion of microtubule-associated protein 1 light 
chain-3B (LC3B) from free form cytosolic LC3B-I (~18 
kDa) to the phosphatidylethanolamine-conjugated LC3B-
II form (~16 kDa), which is tightly bound to the membrane 
of the autophagosome [33]. Edelfosine treatment led to 
the rapid conversion of LC3B-I to LC3B-II after a 3-h 
treatment, reaching its maximum following 24-h treatment 
(Fig. 3B). The formation of LC3B-II, and thereby of 
autophagosomes, was evidenced by both Western blot 
(Fig. 3B) and confocal microscopy (Fig. 3C), this latter 
approach showing the fluorescent punctuate pattern of 
LC3B-II associated with autophagosomal membranes. 
To confirm that edelfosine was increasing the autophagic 
Figure 3: Induction of autophagy in edelfosine-treated U118 cells. (A) Cells untreated (Control) and treated with 10 μM 
edelfosine (EDLF) for 24 h were stained with acridine orange and analyzed by fluorescence microscopy (magnification, 40x). (B) Western 
blot analysis of LC3B-I/II in cells untreated (Control, C) or treated with 10 μM edelfosine (EDLF) for the indicated times. Immunoblotting 
for β-actin was used as an internal control for equal protein loading in each lane. (C) Confocal immunofluorescence microscopy of LC3B 
punctae (red fluorescence) in U118 cells following treatment with 10 μM edelfosine (EDLF) for 3 h. Nuclei were labeled with DAPI (blue 
fluorescence). Bar, 10 μm. (D) Western blot analysis of LC3B-I/II in U118 cells treated with 10 μM edelfosine (EDLF), 25 nM bafilomycin 
A1 (BAF), or both (BAF+EDLF) for 24 h. β-Actin was used as a control for protein loading. (E) Cells were preincubated without or with 
25 nM bafilomycin A1 (BAF) for 1 h, followed by incubation in the absence (Control, C) or presence of 10 μM edelfosine (EDLF) for 6 h, 
and then analyzed by flow cytometry to evaluate apoptosis. Data shown are means ± SD of three independent experiments. (F) MTT assay 
of U118 cells untreated (Control) or treated with 25 nM bafilomycin A1 (BAF) for 1 h, and then incubated in the absence or presence of 
10 μM edelfosine (EDLF) at the indicated time points. Data are expressed as means ± SD of at least three independent experiments, each 
one performed in triplicate. The lower plot shows only the measurements for edelfosine- and bafilomycin A1+edelfosine-treated cells for 
an easier appreciation of changes.
Oncoscience653www.impactjournals.com/oncoscience
flux (autophagic vesicle formation and clearance by 
fusion with lysosomes), we used bafilomycin A1, which 
blocks fusion between lysosomes and autophagosomes 
and therefore leads to autophagosome accumulation. 
We observed an increase in the level of the LC3B-II 
form in cells treated with bafilomycin A1 in comparison 
with untreated control cells as well as with those treated 
with edelfosine alone (Fig. 3D), indicating ongoing 
autophagic flux and the blockade of the fusion between 
autophagosomes and lysosomes. This inhibition of the 
late stages of autophagy scarcely increased the apoptotic 
response (Fig. 3E), and did not increase overall viability 
upon edelfosine incubation, with no significant change 
in MTT reduction (Fig. 3F) or propidium iodide (PI) 
incorporation (data not shown). In addition, pretreatment 
of U118 cells with additional autophagy inhibitors, 
including 20 nM chloroquine or 200 nM wortmannin did 
not affect edelfosine-induced cell death response (data not 
Figure 4: Loss of plasma membrane integrity in edelfosine-treated U118 cells. (A) Percentage of non-viable cells in cells 
untreated (Control) or treated with 10 μM edelfosine (EDLF) for 24 h, as determined by three different methods: cell cycle analysis 
(sub-G1 population measured by flow cytometry), Trypan blue method, and MTT assay (cells unable to metabolize MTT). (B) Annexin 
V/PI staining was analyzed from cells untreated (Control) and treated with 10 μM edelfosine (EDLF) or with 0.5 μM staurosporine (STS) 
at the indicated time points. Lower right quadrant shows annexin V+/PI− cells (early apoptotic cells). Upper right quadrant represents 
annexin V+/PI+ cells (necrotic or late apoptotic cells). Percentages of cells in each quadrant are indicated. Results are representative of three 
independent experiments. (C) Quantification of early apoptotic cells (annexin V+/PI- cells) at the indicated time points, following 10 μM 
edelfosine (EDLF) and 0.5 μM staurosporine (STS) treatments. (D) Cells were incubated with 10 μM edelfosine (EDLF) for the indicated 
periods of time, and then non-viable cells were measured using PI incorporation in non-permeabilized cells (necrosis), LDH release assays, 
and cell cycle analysis (quantification of apoptotic/sub-G1 population). Data shown in A, C and D are means ± SD of three independent 
experiments.
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shown). 
Edelfosine induces mainly necrotic cell death in 
U118 cells
The above results showed that edelfosine-induced 
cell death in U118 cells was not primarily mediated by 
apoptosis or autophagy. The morphological changes 
observed in Fig. 1 apparently corresponded to necrosis, 
and this edelfosine-induced necrotic cell death was 
further assessed by the high presence of non-viable cells 
measured by Trypan blue staining, leading to similar 
figures as those obtained by the MTT assay (Fig. 4A), 
whereas only a minor proportion of cells showed a sub-G1 
Figure 5: Induction of Nec-1-inhibitable necrosis in edelfosine-treated U118 cells. (A) Cell proliferation was measured by 
MTT assay at the indicated time points, after culturing U118 cells without or with 200 μM Nec-1 (Nec-1) for 2 h, and then incubated in 
the absence or presence of 10 μM edelfosine (EDLF). Untreated control cells were run in parallel. Data are expressed as means ± SD of at 
least three independent experiments, each one performed in triplicate. The right plot shows only the measurements for edelfosine- and Nec-
1+edelfosine-treated cells for an easier appreciation of changes. ***, P<0.001 EDLF vs. Nec-1+EDLF, Student’s t test. (B) Quantification 
of U118 cells stained with PI after treatment with 10 μM edelfosine (EDLF) for 4 h without and with a pretreatment of 200 μM Nec-1 
(Nec-1+EDLF) or 200 μM Nec-1s (Nec-1s+EDLF). Data shown are means ± SD of three independent experiments. ***, P<0.001 Nec-
1+EDLF vs. EDLF; ***, P<0.001 Nec-1s+EDLF vs. EDLF, Student’s t test. (C) Representative flow cytometry analysis histograms of 
PI incorporation showing: untretated control cells (Control), 10 μM edelfosine-treated cells (EDLF), and cells treated with Nec-1 (200 
μM, 2 h pretreatment) + EDLF (10 μM) (Nec-1+EDLF) for 4 h. (D, upper pannel) Bright-field microscopy of untreated control cells, 10 
μM edelfosine treated cells for 4 h (EDLF), and cells preincubated with 200 μM NEC-1 for 2 h and then treated for additional 4 h with 
10 μM edelfosine (Nec-1+EDLF). Magnification, 20x. (D, lower pannel) FSC/SSC histograms of the cells treated as in the upper panels, 
showing cellular size (FSC-H) and granularity (SSC-H). Dead cells show lower FSC than living cells. (E) Cells were preincubated without 
or with 200 μM Nec-1 (Nec-1) for 2 h, then incubated in the absence or presence of 10 μM edelfosine (EDLF) for 24 h, and analyzed 
by flow cytometry to evaluate apoptosis. Untreated control cells were run in parallel. Data shown are means ± SD of three independent 
experiments. ***, P<0.001 EDLF vs. Nec-1+EDLF, Student’s t test. (F) Cells were untreated (Control, C), treated with 10 μM edelfosine 
for 24 h (EDLF), pretreated with 200 μM Nec-1 for 2 h and then incubated with edelfosine for 24 h (Nec-1+EDLF), or treated with 200 
μM Nec-1 for 26 h (2 h + 24 h). Cells were then analyzed by immunoblotting using specific antibodies against cleaved caspase-3 and 
LC3B-I/II. Immunoblotting for β-actin was used as an internal control for equal protein loading in each lane. Data shown in C, D and F are 
representative of three independent experiments.
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DNA content (Fig. 4A). To exclude the hypothesis that a 
secondary necrosis following apoptosis was occurring, we 
carried out time-course experiments using annexin V/PI 
assays. An increasing percentage of cells stained positive 
for both annexin V and PI following edelfosine treatment 
(Fig. 4B), whereas the apoptosis-inducer staurosporine 
[30] prompted a high percentage of annexin V+/PI- cells 
(Fig. 4B). After a 24-h treatment, most of the edelfosine-
treated cells were annexin V+/PI+ (Supplementary Fig. S1). 
In contrast to edelfosine, which hardly induced apoptosis 
at early incubation times (Fig. 4C), staurosporine induced 
a high apoptotic response, as assessed by an increase in 
the annexin V+/PI- cell population (Fig. 4C) and by an 
increase in the hypodiploid sub-G1 cell population by cell 
cycle analysis (Fig. 2A). Plasma membrane permeability 
was also confirmed by the release of soluble cytosolic 
LDH into the culture medium at early incubation times 
following edelfosine addition, although LDH release 
showed a slower kinetics than that of PI incorporation 
in non-permeabilized cells (Fig. 4D). A weak increase 
in hypodiploid sub-G1 phase (apoptosis) was detected at 
a slower rate, after 6-9 h of treatment (Fig. 4D). Taking 
together, these data indicate a loss of cellular membrane 
integrity, a hallmark of necrotic cell death, and the onset 
of this type of cell death was detected long before the 
onset of apoptosis in edelfosine-treated cells. Thus, the 
necrotic response induced by edelfosine in U118 cells was 
a rapid and direct one, and not a consequence of secondary 
necrosis that usually takes place in the late phases of 
apoptosis.
Necroptosis inhibitor necrostatin-1 significantly 
increases cellular viability after edelfosine 
treatment
We next examined whether the necrotic cell death 
process induced by edelfosine in U118 cells was a 
modulated one. Necroptosis is a mechanism of regulated 
necrosis that is dependent of receptor-interacting protein 
kinase-1 (RIPK1) and RIPK3 [34-36], and is inhibited by 
necrostatin-1 (Nec-1), a specific inhibitor of RIPK1 [37, 
38]. Here, we found that Nec-1 was able to improve overall 
viability of edelfosine-treated U118 cells, as assessed 
by protecting MTT metabolism (Fig. 5A), reducing PI 
incorporation in non-permeabilized cells (Fig. 5B and C), 
and preventing necrotic morphology evaluated by either 
bright field microscopy (Fig. 5D, upper) or SSC/FSC 
flow cytometry analysis (Fig. 5D, lower). Preincubation 
of Nec-1 also induced a slight, but significant, increase 
in apoptosis in edelfosine-treated cells, as assessed by an 
increase in the level of sub-G1 DNA cell population (Fig. 
5E) and caspase-3 activation (Fig. 5F). In addition, Nec-
1 preincubation inhibited edelfosine-induced autophagy 
(Fig. 5F), suggesting that autophagy is a side-effect of 
the stress imposed to the U118 cells undergoing necrosis. 
Because Nec-1 is also known to inhibit indoleamine-2,3-
dioxygenase (IDO) [39-41], we tested the effect of Nec-1s, 
a more specific RIPK1 inhibitor lacking the IDO-targeting 
effect [38, 40]. Nec-1s showed a similar protective 
effect to that observed with Nec-1, highly reducing PI 
incorporation in edelfosine-treated U118 cells (Fig. 5B), 
and thereby the effect of Nec-1 on PI uptake was not due 
to suppression of IDO activity.
Figure 6: Relative protein levels of RIPK1, Fas/CD95, FADD and procaspase-8 in U118, HeLa and Jurkat cells. (A) 
U118, HeLa and Jurkat cell lines were analyzed by immunoblotting using specific antibodies against RIPK1, Fas/CD95 and FADD. 
Immunoblotting for β-actin was used as an internal control for equal protein loading in each lane. (B) U118, HeLa and Jurkat cells untread 
and treated with 10 μM edelfosine (EDLF) for 24 h were analyzed by immunoblotting using a specific antibody that recognizes full-length 
57-kDa procaspase-8 and p43/41 cleaved active caspase-8 fragments. The molecular weight of each immunodetected band is indicated. 
Data shown are representative of three experiments.
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U118 cells express RIPK1 and have low levels of 
procaspase-8 and extrinsic apoptotic pathway 
molecules 
Edelfosine has been reported to induce apoptosis 
in a variety of hematological cancer cells through the 
recruitment into lipid rafts of extrinsic apoptotic pathway 
molecules forming clusters of Fas/CD95 death receptor 
and downstream signaling molecules, including FADD 
and procaspase-8 [22, 23, 28, 42, 43]. Here we found that 
U118 expressed RIPK1, a major protein in necroptosis, 
but very low levels of Fas/CD95, FADD and 57-kDa 
procaspase-8, critical proteins involved in the extrinsic 
pathway of apoptosis, as compared to HeLa (human 
cervical carcinoma) and Jurkat (human acute T-cell 
leukemia) cells (Fig. 6A and B), two cancer cell lines that 
Figure 7: Effect of RIPK3 silencing on edelfosine-induced cell death in U118 cells. (A) Immunoblot to assess knockdown of 
RIPK3 protein following transfection with RIPK3-siRNA (100 nM). β-Actin was used as a control for protein loading. Protein expression 
was evaluated 5 days after transfection. (B) U118 untreated control cells, cells transfected with a non-targeting sequence (siRNA Control), 
and cells transfected with 100 nM RIPK3-siRNA were incubated with 10 μM edelfosine for 20 h in the absence or presence of z-VAD-fmk, 
and apoptosis was evaluated by flow cytometry analysis of the cell cycle (sub-G1 cell population). Data shown are means ± SD of three 
independent experiments. ***, P<0.001 RIPK3-siRNA+EDLF vs. Control-siRNA+EDLF; ***, P<0.001 z-VAD+RIPK3-siRNA+EDLF 
vs. RIPK3-siRNA+EDLF, Student’s t test. (C) Non-targeting siRNA (control)- and RIPK3-siRNA-transfected cells treated with 10 μM 
edelfosine were analyzed by cell cycle flow cytometry (sub-G1 population and percentages of sub-G1 cells are indicated in each histogram) 
after 20 h drug treatment (upper panel); brightfield microscopy to visualize cell morphology after 4 h edelfosine treatment (middle panel), 
and DAPI staining of nuclei following 20 h drug treatment (lower panel). (D) Immunoblotting for cleaved caspase-3 forms and caspase-8 
(procaspase-8 and cleaved p18 fragment) in untreated cells (Control), and in control cells, and RIPK3-siRNA-transfected cells treated 
with edelfosine 10 μM for 9 h. β-Actin was used as a control for protein loading. (E) U118 cells were untreated (C) or treated with 
necrosulfonamide (NSA) at the indicated concentrations for 21 h, treated with 10 μM edelfosine for 20 h, and pretreated with NSA for 1 h 
and then treated with edelfosine for 20 h. Then apoptosis was evaluated by flow cytometry analysis of the cell cycle (sub-G1 cell population). 
Data shown are means ± SD of three independent experiments. **, P<0.01 and ***, P<0.001 NSA+EDLF vs. EDLF, Student’s t test.
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Figure 8: Changes in intracellular free calcium concentration in edelfosine-treated U118 cells. (A) Cells were treated with 
10 μM edelfosine (EDLF) for the indicated times followed by incubation with Fluo-4-AM for 30 min at 37ºC, before being analyzed by 
fluorescence microscopy. (B) Cells were treated with 10 μM edelfosine (EDLF) for the indicated times, then incubated with Fluo-4-AM 
dye for 30 min and fluorescence intensity was measured by flow cytometry. (C) Untreated control cells (C), cells treated with 10 μM 
edelfosine (E) for the indicated times, or cells incubated with 4 μM BAPTA for 1 h and then treated with 10 μM edelfosine (B+E) for the 
indicated times, were analyzed by immunoblotting using a specific antibody for LC3B-I/II. (D) MTT assays were conducted after culturing 
U118 cells without or with 4 μM BAPTA-AM for 1 h, and then incubated in the absence or presence of 10 μM edelfosine (EDLF) at the 
indicated time points. Untreated control cells were run in parallel. Data shown are means ± SD of three independent experiments, each one 
performed in triplicate. The lower plot shows only the measurements for edelfosine- and BAPTA-AM+edelfosine-treated cells for an easier 
appreciation of changes. (E) Cells were preincubated without or with 4 μM BAPTA-AM for 1 h, and then treated with 10 μM edelfosine 
(EDLF) for the indicated time points and analyzed by flow cytometry to evaluate apoptosis. **, P<0.01 EDLF vs. BAPTA+EDLF, Student’s 
t test. (F) Cells treated with 10 μM edelfosine for the indicated times without (EDLF) or with Nec-1 pretreatment (Nec-1+EDLF) were 
incubated with Fluo-4-AM for 30 min at 37ºC, and fluorescence was measured by flow cytometry. (G) Cells incubated for 1 h without or 
with 10 mM EGTA, and then in the absence or presence of 10 μM edelfosine (EDLF) for 4 h, were incubated with Fluo-4-AM for 30 min 
and fluorescence was measured by flow cytometry. Untreated control cells were run in parallel. Data are expressed as means ± SD of three 
independent experiments. **, P<0.01, Student’s t test. (H) Cells were pretreated with EGTA (10 mM) or 2-APB (60 μM) + EGTA (10 mM) 
for 1 h, and then incubated in the absence or presence of 10 μM edelfosine (EDLF) for 24 h, and analyzed by flow cytometry to evaluate 
apoptosis. Untreated control cells were run in parallel. Data are expressed as means ± SD of three independent experiments. ***, P<0.001 
EGTA+EDLF vs. EDLF or 2-APB+EGTA+EDLF, Student’s t test.
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readily undergo apoptosis following edelfosine treatment 
[22, 44]. In addition, as shown in Fig. 6B, a high level 
of caspase-8 activation, assessed by the generation of its 
43/41-kDa cleaved form, was detected in both HeLa and 
Jurkat cells upon edelfosine treatment, but not in U118 
cells. These data support the notion that low levels of 
procaspase-8 or lack of caspase-8 activation, together 
with a high RIPK1/procaspase-8 ratio, might favor the 
induction of necroptotic cell death in U118 cells.
Involvement of RIPK3 in edelfosine-mediated 
necroptosis in U118 cells
Necroptosis has been shown to depend on the 
activation of RIPK1 and RIPK3, which associate forming 
complexes that are referred to as necrosomes [45], RIPK3 
being identified as a crucial regulator of necroptosis [46, 
47]. We found that U118 cells expressed RIPK3, and 
RIPK3 silencing by using siRNA (Fig. 7A), dramatically 
reduced (~80%) necrotic phenotype and, similarly to what 
was observed by using necrostatin-1, induced apoptotic 
cell death following edelfosine treatment, as assessed by 
an increase in sub-G1 cell population through cell cycle 
analysis, and by the presence of morphologic features of 
apoptosis, including cell surface blebbing and chromatin 
condensation in DAPI-stained nuclei in edelfosine-treated 
U118 cells (Fig. 7B and C). This induction of apoptosis 
was further supported by caspase-3 and caspase-8 
activation (Fig. 7D) and its total inhibition by the pan-
caspase inhibitor z-VAD-fmk (Fig. 7B). Cells transfected 
with a non-targeting sequence behaved as untreated 
control cells (Fig. 7B). The mixed lineage kinase domain-
like protein (MLKL) has been identified as a key mediator 
of necrosis signaling downstream of RIPK3 and the small 
molecule called (E)-N-(4-(N-(3-methoxypyrazin-2-yl)
sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide, 
usually referred to as necrosulfonamide, blocks necrosis 
downstream of RIPK3 by covalently modifying MLKL 
[48]. Here, we found that necrosulfonamide also increased 
the induction of apoptosis in edelfosine-treated U118 cells 
(Fig. 7E).
Edelfosine-induced U118 necroptotic cell death is 
independent of changes in intracellular calcium 
concentration
Because a connection between Ca2+ homeostasis and 
necrosis has been suggested [49, 50], we next examined 
whether calcium was involved in edelfosine-induced cell 
death by measuring intracellular calcium levels using 
the calcium indicator dye Fluo-4 AM. Incubation of 
U118 cells with edelfosine led to a rapid and persistent 
increase in the free intracellular calcium concentration 
(Fig. 8A and B). Following 24-h drug incubation, swollen 
Figure 9: Schematic model for edelfosine-induced cell death in U118 cells. (upper) This is a schematic diagram that depicts 
the cell death mechanisms triggered during the edelfosine killing action in U118 glioblastoma cells, and highlights the involvement of 
RIPK1/RPK3-mediated necroptotosis in the process. (lower) When necroptosis is inhibited, the caspase-dependent apoptotic response is 
potentiated following edelfosine treatment. See the text for details.
Oncoscience659www.impactjournals.com/oncoscience
dying cells still displayed bright green fluorescence, 
indicative of a high intracellular calcium concentration 
(data not shown). The membrane permeable calcium 
chelator BAPTA-AM, that inhibited ~55% the increase 
in free calcium concentration induced by edelfosine 
treatment, strongly diminished edelfosine-induced 
autophagy as assessed by a lower number of AVOs 
(data not shown) and a reduced conversion of LC3B-I to 
LC3B-II in drug-treated U118 cells (Fig. 8C). However, 
BAPTA-AM preincubation did not affect the overall cell 
survival measured by MTT assay (Fig. 8D), but slightly 
increased the apoptotic response, although the difference 
was only statistically significant at 9-h treatment (Fig. 
8E). Furthermore, inhibition of necroptosis by Nec-1 
prior to edelfosine treatment led to a lower increase in 
the intracellular calcium level, but this effect was not 
statistically significant (Fig. 8F). Preincubation with 
the extracellular calcium chelator EGTA dramatically 
diminished the level of intracellular calcium (Fig. 8G) 
and slightly potentiated edelfosine-induced apoptosis 
(Fig. 8H), this increased apoptotic response being blocked 
by the inhibitor of inositol 1,4,5-trisphosphate-mediated 
Ca2+ release 2-APB (2-aminoethoxydiphenyl borate) (Fig. 
8H). Taken together, these data suggest that the increase 
in intracellular free calcium concentration induced by 
edelfosine is prompted mainly through an inward flux 
of extracellular calcium ions, a process that could be 
rather independent of, but concomitant with, the onset 
on necroptosis, and that is suggested to promote a rather 
antiapoptotic and proautophagic response. However, when 
the influx of extracellular free calcium is blocked, the 
previously reported release of intracellular free calcium 
from internal stores elicited by edelfosine in solid tumor 
cells [24, 27] seems to play a role in the triggering of the 
minor apoptotic cell death response triggered in U118 
cells.
DISCUSSION
The results reported here show for the first time that 
an APL molecule, edelfosine, is able to induce necroptosis 
in a tumor cell. The ether phospholipid edelfosine induces 
a rapid necrotic cell death in human U118 glioblastoma 
cells, which is inhibited by the specific RIPK1 inhibitors 
Nec-1 and Nec-1s as well as by RIPK3 silencing, and 
accounts for most of the cell death (~80%) occurring 
in edelfosine-treated U118 cells, thus involving both 
RIPK1 and RIPK3 in the cell death process. Our data also 
indicate that edelfosine elicits a minor caspase-dependent 
apoptotic response (~18%) in U118 cells. Necroptosis 
is a programmed and regulated necrosis process that is 
dependent on RIPK1 and RIPK3 [34, 35], and has been 
linked to death receptor activation [34, 51, 52]. Edelfosine 
has been found to promote apoptosis in a wide number 
of cancer cells through the involvement of Fas/CD95 
death receptor [20, 22, 23, 53, 54], but the results reported 
here suggest that U118 glioma cells have some molecular 
features that make them prone to undergo this necroptotic 
cell death instead of apoptosis upon edelfosine incubation. 
In this regard, the relative ratio of RIPK1/procaspase-8 
level was much higher in U118 cells than in HeLa and 
Jurkat cells, two cancer cell lines that readily undergo 
apoptosis following edelfosine treatment [22, 44], and 
might predispose U118 cells to undergo necroptosis upon 
edelfosine treatment. Our results agree with the notion that 
the mode of cell death is determined whether the cells are 
apoptosis-prone or apoptosis-reluctant, depending on the 
apoptotic machinery and levels of procaspases present in 
each specific cell type [55-57]. Thus, the cell’s ability to 
undergo a certain type of cell death is mainly dictated by 
its inherent features of gene expression patterns related 
to cell death and/or by the putative activation of specific 
signaling pathways that modulate cell death. On these 
grounds, the data reported here suggest that U118 glioma 
cells are apoptosis-reluctant but necroptosis-prone, and 
their proneness to undergo necroptotic cell death is easily 
triggered by edelfosine. Interestingly, our results also show 
that necroptosis inhibition by RIPK1 inhibition and RIPK3 
silencing causes U118 cells to undergo caspase-dependent 
apoptosis upon edelfosine treatment, thus turning the cell 
death response to caspase-dependent apoptosis when 
necroptosis is blocked.
Edelfosine has been previously reported to promote 
caspase-independent cell death in LN18 malignant glioma 
cell line [58]. Another APL, perifosine, has been reported 
to induce caspase-independent cell death in human 
prostate cancer PC-3 cells [59]. The APL miltefosine 
promotes cell-type-dependent apoptotic and non-apoptotic 
cell death processes in several human breast cancer cell 
lines [60]. However, necroptosis was not examined in the 
above studies.
Temozolomide, considered as the new gold 
standard for brain tumor therapy, has been reported to 
induce autophagy in malignant glioma cells [9]. Our data 
indicate that triggering of autophagy by edelfosine was 
not relevant for the induction of the major necroptotic 
cell death response. Suppression of autophagy promoted 
a slight increase of apoptosis, thus suggesting autophagy 
could work as a weak protective scenario for apoptosis 
in edelfosine-treated U118 cells. The potent necroptotic 
activity of edelfosine was exerted when this ether lipid 
was used at 10 µM, a concentration that fits well the drug 
plasma levels (10-20 µM) found in pharmacokinetic and 
in vivo studies [25, 26, 61]. Temozolomide at the rather 
high concentration, but clinically achievable, of 100 µM 
and after 72 h incubation induces autophagy, but not 
apoptosis in several malignant glioma cell lines [8]. On 
these grounds, the results reported here suggest that certain 
features of U118 glioma cells make them particularly 
sensitive to edelfosine.
We also found that edelfosine prompted an increase 
in free intracellular Ca2+ concentration in U118 cells that 
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was mainly due to the entry of extracellular calcium. 
This increase in intracellular Ca2+ was not relevant to the 
induction of the necroptotic response, but seemed to be 
involved in the triggering of autophagy.
Figure 9 depicts a scheme for the relative 
participation of three major types of cell death in the 
demise of U118 cells upon edelfosine treatment. U118 
cells treated with edelfosine primarily undergo necroptosis, 
involving RIPK1 and RIPK3 (Fig. 9, upper), and 
inhibition of this necrotic response results in an increase 
in caspase-dependent apoptosis (Fig. 9, lower), thus 
highlighting the potent pro-cell death signaling triggered 
by edelfosine in this glioma cell line. The fact that 
blockade of necroptosis led to increased apoptosis shows 
that edelfosine can activate both cell death pathways in 
U118 cells, and therefore it can be an effective drug for the 
demise of glioblastoma cells. This warrants further studies 
on the putative effects of this ether lipid in glioblastoma. 
The data reported here also suggest that U118 cells can 
constitute a useful cell model to elucidate the mechanisms 
that dictate the cellular decision to undergo alternative cell 
death pathways, such as apoptosis or necroptosis, as well 
as the processes mediating the triggering and execution 
of necroptosis. Our data also highlight the use of U118 
glioma cells for the search of new therapeutic approaches 
to treat glioblastoma by promoting distinct types of cell 
death.
METHODS
Cell culture
Cells were grown at 37ºC in DMEM (Gibco, Life 
Technologies Corporation) (U118 and HeLa) or RPMI-
1640 (Gibco) (Jurkat) supplemented with 10% heat-
inactivated FBS, 2 mM L-glutamine, 100 U/ml penicillin, 
100 µg/ml streptomycin in a humidified atmosphere 
containing 5% CO2.
Cell proliferation and viability assays
Cell proliferation and viability was assessed 
by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay, through MTT 
conversion into colored formazan product by 
metabolically active cells [62]. Absorbance was measured 
using a spectrophotometric microplate reader with 
reference filter at 630 nm and reading filter at 570 nm. 
Each determination was performed in triplicate.
Cell viability was also evaluated by using Trypan 
Blue dye reagent. Non-viable cells stained blue, while 
viable cells excluded Trypan Blue and showed normal 
refringent cytoplasm. Samples were counted under a light 
microscope, and the percentage of non-viable cells was 
determined.
Cytotoxicity was also analyzed by lactate 
dehydrogenase (LDH) assay by using the Cytotoxicity 
Detection Kit (LDH) (Roche, Basel, Switzerland), 
according to the manufacturer’s instructions. Absorbance 
was read in a spectrophotometric microplate reader at 450 
nm. Values were normalized as percentages to untreated 
cells and shown as % viability relative to untreated cells.
Edelfosine was obtained from R. Berchtold 
(Biochemisches Labor, Bern, Switzerland). A stock 
solution was prepared at 2 mM in culture medium 
containing 10% (v/v) FBS by heating at 50°C for 30 min, 
as previously described [15].
Measurement of apoptosis by flow cytometry
Quantitation of apoptotic cells was calculated as the 
percentage of cells in the sub-G1 region (hypodiploidy) 
following cell-cycle analysis as previously described [17].
Analysis of DNA fragmentation in agarose gels
To assess apoptosis, we isolated fragmented DNA as 
previously described [14, 63], and internucleosomal DNA 
degradation was detected by electrophoretic analysis in 
1% agarose gels (containing 0.5 µg/ml ethidium bromide) 
and UV transillumination.
PI exclusion assay
This assay was used to evaluate plasma membrane 
integrity. Cells, resuspended in PBS containing 10 µg/
ml PI, were incubated in the dark for 15 min at room 
temperature, and then analyzed by flow cytometry (590 
nm) to determine the proportion of cells with increased 
permeability to PI (PI+-cells) as the percentage of cells 
with increased red fluorescence (strong shift in FL-2 
values, log scale) with respect to the basal red fluorescence 
observed in untreated control cells.
Annexin V/PI assay
Control and treated cells were collected, washed 
with PBS, and incubated in 100 µl annexin V binding 
buffer 1x (BD Pharmingen, San Jose, CA) containing 5 
µl annexin V-FITC (BD Pharmingen) and 10 µg/ml PI for 
15 min at room temperature. Samples were analyzed by 
flow cytometry with simultaneous monitoring of green 
fluorescence (530 nm, 30 nm band-pass filter) for annexin 
V-FITC and red fluorescence (long-pass emission filter 
that transmits light >650 nm) for PI.
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Supravital cell staining with acridine orange
Cells were incubated with 1 µg/ml acridine orange 
(Molecular Probes, Leiden, The Netherlands) for 15 min 
at 37ºC, and then analyzed under a Nikon Eclipse Ti-S 
fluorescence microscope using an excitation filter of 550 
nm (540-560 nm) and a long pass >610 nm emission/
barrier filter.
Measurement of intracellular calcium
Cells were incubated with 2 µM Fluo-4 AM dye 
(Molecular Probes) for 30 min at 37ºC, and then analyzed 
by fluorescence microscopy or by flow cytometry.
siRNA transfection
ON-TARGETplus SMART pool for human RIPK3 
(L-003534-00) siRNA, which included a mixture of four 
specific siRNAs provided as a single reagent, as well 
as a non-targeting pool siRNA (D-001810-10-05) were 
purchased from Thermo Scientific (Pittsburgh, PA). 
U118 cells at a density of 8 × 104 cell per well in 6-well 
plates were transfected with 100 nM RIPK3-siRNA using 
siPORT NeoFX transfection agent (Life Technologies) 
according to the manufacturer’s instructions. Protein 
knockdown was assessed between two and five days after 
transfection, and best knockdown rates were obtained 
following 5 days after transfection and used in the 
experiments shown in this work. Efficiency of RIPK3 
knockdown was quantified with ImageJ software after 
Western blotting and using β-actin as protein control.
Western blot analysis
Thirty to fifty micrograms of protein extracts from 
4-5 x 106 cells, prepared as previously described [24] 
were subjected to SDS-polyacrylamide gels, transferred 
to Immobilon-P PVDF membranes (Merck Millipore, 
Darmstadt, Germany), blocked with 5% (w/v) defatted 
milk powder in TBST (50 mM Tris–HCl, pH 8.0, 150 mM 
NaCl, 0.1% Tween 20) for 1 h at room temperature, and 
incubated for 1 h at room temperature, or overnight at 
4 °C, with the following specific antibodies: anti-17- and 
19-kDa cleaved caspase-3 (Asp 175) rabbit polyclonal 
antibody (1:1000 dilution, Cell Signaling Technology); 
C2.10 anti-116 kDa PARP mouse monoclonal antibody, 
that also detects the 85 kDa cleavage product (1:1000 
dilution, BD Biosciences); anti-18-kDa (LC3B-I)/16-kDa 
(LC3B-II) rabbit polyclonal antibody (1:1000 dilution, 
Cell Signaling Technology); anti-79-kDa RIPK1 rabbit 
polyclonal antibody (1:1000 dilution, Cell Signaling 
Technology); anti-62-kDa RIPK3 rabbit monoclonal 
antibody (1:1000 dilution, Cell Signaling Technology); 
anti-48-kDa Fas/CD95 rabbit polyclonal antibody (1:500 
dilution, Santa Cruz Biotechnology Inc., Santa Cruz, 
CA); anti-24-kDa FADD mouse monoclonal antibody 
(1:1000 dilution, BD Transduction Laboratories); 
1C12 anti-57 kDa procaspase-8 mouse monoclonal 
antibody, that also detects the cleaved p43/41 and p18 
subunits (1:1000 dilution, Cell Signaling Technology). 
Secondary antibodies were anti-mouse or anti-rabbit 
immunoglobulins conjugated to horseradish peroxidase 
(GE Healthcare, Princeton, NJ). Signals were detected 
using an ECL kit (GE Healthcare).
Time-lapse videomicroscopy
Cells were recorded by time-lapse microscopy 
using a Nikon Eclipse TE2000-E microscope that was 
enclosed in a Plexiglass box where cells were maintained 
under a humidified air of 5% CO2 at 37ºC using OKO-
Lab technology. MetaMorph software was used for image 
acquisition and processing. Frames were taken every 10 
min for 9 h.
Confocal microscopy
1 × 106 cells were seeded on 6-well plates, each 
well containing a sterile glass coverslip coated with poly-
L-lysine. Untreated and edelfosine-treated cells were 
fixed in formaldehyde (4% in PBS) for 20 min at room 
temperature. After fixation, cells were permeabilized in 
cold PBS containing 0.1% Triton X-100 for 1 min and 
rinsed thoroughly with PBS. Staining was performed 
incubating the coverslip with a specific anti-LC3B rabbit 
polyclonal antibody (Cell Signaling Technology) (1:100 
dilution) for 1-h at room temperature, followed by 1-h 
at room temperature with CY3-conjugated anti-rabbit 
immunoglobulin (Ig) antibody (diluted 1:150 in PBS; 
Jackson ImmunoResearch, West Grove, PA), and DAPI 
staining (0.5 μg/ml; 5 min). Each incubation was followed 
by 2 washes in PBS. Stained coverslips were then mounted 
on slides using the antifading reagent SlowFade Gold 
(Invitrogen, Eugene, OR) to preserve fluorescence signal 
intensity. Samples were analyzed by microscopy using a 
confocal Leica SP5 microscope and LAS AF software.
Statistical analysis
Results are expressed as means ± SD of the number 
of experiments indicated. Comparisons between two 
experimental groups were determined using Student’s 
t-test with P-value<0.05 indicating statistical significance.
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